DEACTIVATE by Xenex: Handheld LED Device Can Quickly Disinfect Surfaces in Confined Spaces

February 1

Deactivate is a high-powered, handheld LED device designed to quickly disinfect surfaces in confined spaces.

Xenex is known for its LightStrike™ Germ-Zapping Robots™, which have been deployed by hundreds of healthcare facilities worldwide for no-touch room disinfection. As a result of the COVID-19 pandemic, LightStrike robots are now used in airports, schools, hotels, sports arenas, police stations and correctional facilities, convention centers, and more to quickly disinfect large rooms and areas.

Recognizing the need for targeted disinfection in small spaces and compact areas, Xenex has launched Deactivate, which utilizes high-powered LEDs to create ultraviolet (UV) light proven to deactivate pathogens, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. Deactivate does not require warm-up or cool-down time, and does not leave behind any chemical residue. Post-disinfection, the area is immediately available for use.

“Our mission is to stop the pain and suffering caused by infections by destroying the pathogens that cause them. There are many businesses that need targeted, rapid disinfection, especially compact areas like dental exam rooms, ambulances, office cubicles, and cockpits. We wanted to offer an effective technology for disinfecting small spaces that are hard to clean and that’s what Deactivate provides,” said Irene Hahn, senior vice president of sales and marketing for Xenex.

Evidence-based. Testing performed at the Texas Biomedical Research Institute demonstrated that the Deactivate device achieves a 99% level of disinfection against SARS-CoV-2 in 30 seconds at 1 meter, 99% against vegetative bacteria (methicillin-resistant Staphylococcus aureus – also known as MRSA, Escherichia coli – also known as E.coli) in 1 minute at 1 meter, and 99% against bacterial spores in 2 minutes at 1 meter.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”